![These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS. TERIFLUNOMIDE tablets, for oral use Initial U.S. Approval: 2012 These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS. TERIFLUNOMIDE tablets, for oral use Initial U.S. Approval: 2012](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-05.jpg&id=694996)
These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS. TERIFLUNOMIDE tablets, for oral use Initial U.S. Approval: 2012
![Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio®'- for Treatment of Multiple Sclerosis in India Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio®'- for Treatment of Multiple Sclerosis in India](https://mma.prnewswire.com/media/793371/Aubagio_Teriflunomide_14_mg.jpg?p=twitter)
Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio®'- for Treatment of Multiple Sclerosis in India
![JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis - JAMP Pharma JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis - JAMP Pharma](https://www.jamppharma.ca/wp-content/uploads/2022/05/JAMP-Teriflunomide.png)